The estimated Net Worth of Joseph H. Gardner is at least $997 ezer dollars as of 10 July 2019. Joseph Gardner owns over 5,000 units of Aerpio Pharmaceuticals Inc stock worth over $996,642 and over the last 7 years Joseph sold ARPO stock worth over $0.
Joseph has made over 2 trades of the Aerpio Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Joseph bought 5,000 units of ARPO stock worth $4,050 on 10 July 2019.
The largest trade Joseph's ever made was buying 5,000 units of Aerpio Pharmaceuticals Inc stock on 10 July 2019 worth over $4,050. On average, Joseph trades about 1,429 units every 1 days since 2017. As of 10 July 2019 Joseph still owns at least 453,019 units of Aerpio Pharmaceuticals Inc stock.
You can see the complete history of Joseph Gardner stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI, OH, 45242.
Over the last 7 years, insiders at Aerpio Pharmaceuticals Inc have traded over $1,836,659 worth of Aerpio Pharmaceuticals Inc stock and bought 3,976,967 units worth $14,245,937 . The most active insiders traders include Muneer A Satter, Advisors Llc Orbi Med Capit... és Chau Quang Khuong. On average, Aerpio Pharmaceuticals Inc executives and independent directors trade stock every 38 days with the average trade being worth of $486,886. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 8 December 2020, trading 21,400 units of ARPO stock currently worth $41,944.
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.
Aerpio Pharmaceuticals Inc executives and other stock owners filed with the SEC include: